USE OF CANNABIDIOL IN PATIENTS WITH REFRACTORY EPILEPSY: AN INTEGRATIVE REVIEW OF CLINICAL AND THERAPEUTIC EVIDENCE
Keywords:
Cannabidiol, Refractory Epilepsy, Adjunct Treatment, Epileptic Syndromes, Quality of LifeAbstract
This study presents an integrative review of the clinical and therapeutic evidence available on the use of cannabidiol (CBD) in patients with refractory epilepsy. This condition is characterized by resistance to conventional antiepileptic treatments, making seizure control a significant challenge for both patients and healthcare professionals. CBD, a non-psychoactive compound derived from Cannabis sativa, has shown promising potential in managing epileptic seizures, particularly in syndromes such as Dravet and Lennox-Gastaut. Based on the analysis of recent clinical studies, benefits have been observed regarding seizure frequency reduction, improved quality of life, and an acceptable safety profile when used under medical supervision. However, further studies are needed to standardize dosages and assess long-term effects. This review also highlights the importance of developing public policies that regulate access to treatment, ensuring safety and equity in the provision of this therapy.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Álvaro Dias de Alkmin Filho, David José Conceição Vila, Ramon de Mendonça Correia, Marcela Marinho de Oliveira, Lívia Ayres Mendes Khair, Thallía Vitória Oliveira Mota, Rafael Costa dos Santos, Ednei Luiz França Cajá, Bruna Lopes Alegrio, Joel Mariano Gomes Pereira, Nathália Déo Gasparotto, Mateus Giovani Senna, Valéria Goulart Viana, Rafaela Thaís Schalanski, Amanda Santana de Medeiros Dalla Pria Pria, Lucas da Cruz Alarcon Lima, Fernando Antonio Barbosa da Silva Filho, Lucas Teixeira Campos Queiroz, Camila Cristina Prado, Marcella de Fátima Lomeu Marinho
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
